The Evolving Arena of Ovarian Cancer Maintenance Therapy

被引：1
作者：
Markman, Maurie [1 ,2 ]
机构：
[1] Canc Treatment Ctr Amer, 1331 East Wyoming Ave, Philadelphia, PA 19124 USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
来源：
ONCOLOGY | 2019年 / 97卷 / 04期
关键词：
Ovarian cancer; Maintenance therapy; Bevacizumab; PARP inhibitors; DOUBLE-BLIND; EPITHELIAL OVARIAN; ONCOLOGY-GROUP; OPEN-LABEL; PLATINUM; BEVACIZUMAB; RECURRENT; TRIAL; CHEMOTHERAPY; PACLITAXEL;
D O I：
10.1159/000501618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Based on the results of several phase 3 randomized trials, "maintenance therapy" (prolonged treatment after an initial response to cytotoxic chemotherapy) has assumed a critical role in the routine care of advanced epithelial ovarian cancer. While earlier data had provided support for this therapeutic concept in disease management (e.g., multiple cycles of single-agent paclitaxel following a clinical complete response to a platinum/paclitaxel regimen), more recent data has revealed both the efficacy and safety of the anti-angiogenesis agent, bevacizumab, and several PARP inhibitors when employed in this clinical setting. (C) 2019 S. Karger AG, Basel
引用
收藏
页码：202 / 205
页数：4
相关论文
共 16 条
  • [11] Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial
    Markman, Maurie
    Liu, P. Y.
    Moon, James
    Monk, Bradley J.
    Copeland, Larry
    Wilczynski, Sharon
    Alberts, David
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 114 (02) : 195 - 198
  • [12] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
    Mirza, M. R.
    Monk, B. J.
    Herrstedt, J.
    Oza, A. M.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J. A.
    Lorusso, D.
    Vergote, I.
    Ben-Baruch, N. E.
    Marth, C.
    Madry, R.
    Christensen, R. D.
    Berek, J. S.
    Dorum, A.
    Tinker, A. V.
    du Bois, A.
    Gonzalez-Martin, A.
    Follana, P.
    Benigno, B.
    Rosenberg, P.
    Gilbert, L.
    Rimel, B. J.
    Buscema, J.
    Balser, J. P.
    Agarwal, S.
    Matulonis, U. A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) : 2154 - 2164
  • [13] Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
    Moore, K.
    Colombo, N.
    Scambia, G.
    Kim, B. -G.
    Oaknin, A.
    Friedlander, M.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Mathews, C.
    Liu, J.
    Lowe, E. S.
    Bloomfield, R.
    DiSilvestro, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26) : 2495 - 2505
  • [14] A Phase 3 Trial of Bevacizumab in Ovarian Cancer
    Perren, Timothy J.
    Swart, Ann Marie
    Pfisterer, Jacobus
    Ledermann, Jonathan A.
    Pujade-Lauraine, Eric
    Kristensen, Gunnar
    Carey, Mark S.
    Beale, Philip
    Cervantes, Andres
    Kurzeder, Christian
    du Bois, Andreas
    Sehouli, Jalid
    Kimmig, Rainer
    Staehle, Anne
    Collinson, Fiona
    Essapen, Sharadah
    Gourley, Charlie
    Lortholary, Alain
    Selle, Frederic
    Mirza, Mansoor R.
    Leminen, Arto
    Plante, Marie
    Stark, Dan
    Qian, Wendi
    Parmar, Mahesh K. B.
    Oza, Amit M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26) : 2484 - 2496
  • [15] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    [J]. LANCET ONCOLOGY, 2017, 18 (09) : 1274 - 1284
  • [16] Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
    Pujade-Lauraine, Eric
    Hilpert, Felix
    Weber, Beatrice
    Reuss, Alexander
    Poveda, Andres
    Kristensen, Gunnar
    Sorio, Roberto
    Vergote, Ignace
    Witteveen, Petronella
    Bamias, Aristotelis
    Pereira, Deolinda
    Wimberger, Pauline
    Oaknin, Ana
    Mirza, Mansoor Raza
    Follana, Philippe
    Bollag, David
    Ray-Coquard, Isabelle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (13) : 1302 - +
12